TrialNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
A phase 1, safety, tolerability, and pharmacokinetics study of bisnorcymserine, a highly selective inhibitor of butyrylcholinesterase.
Iason Tzieras et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.